Drug Hunter

The "necessary nitrogen" atom has become a fixture in the medicinal chemist's toolbox, and phenyl-to-pyridine ring swaps remain one of the most popular bioisosteric replacements. In this insights article, we focus on an emerging bioisostere, the pyridazin

The First Time Disclosures session at the EFMC International Symposium on Medicinal Chemistry 2026 in Basel, Switzerland, featured eight small molecules presented across two sessions. Organized by the Division of Medicinal Chemistry & Chemical Biology of

Covalent drug discovery continues to expand across target families, modalities, and therapeutic areas. Drug Hunter's covalent warhead reactivity cheat sheet summarizes the relative reactivity of major covalent warhead classes and highlights real-world med

Golidocitinib (AZD4205/DZD4205) is an oral, selective JAK1 inhibitor discovered by AstraZeneca and developed by Dizal for oncology. The molecule applies JAK1-selective pathway inhibition to r/r PTCL, aiming to suppress JAK-STAT-driven lymphoma biology whi

In July 2026, enlicitide (Lipfendra) became the first oral PCSK9 inhibitor approved by the FDA-a feat once thought impossible due to the flat PCSK9-LDLR interaction surface. In Ph. 3 trials, enlicitide demonstrated antibody-like efficacy in adults with hy

Each month, Drug Hunter reviews thousands of drug discovery IP disclosures to curate the patents and applications most likely to move the field. From our weekly updated search table, we spotlight standout filings from July 2026, including claims, structur

The First Time Disclosures at the ACS Fall 2026 meeting in Chicago featured 13 small molecule compounds across two sessions, offering a first look at the next wave of clinical candidates. Organized by the ACS MEDI Division and chaired by H. Rachel Lagiako

AI agents are often viewed as tools for molecular design, yet their greatest near-term impact on drug discovery may instead come from automating routine, knowledge-intensive work. This review explores how rapidly improving general-purpose AI agents are be

The latest INN list contains an unusually high number of radiopharmaceuticals, including many with the chelator suffix -xetan. These metal chelators include the established DOTA scaffold and related motifs such as DOTAGA and DOTAM. Modifications to these

Oligonucleotide therapeutics have evolved from a scientific concept into a clinically validated drug modality across multiple indications. Their therapeutic premise lies in their ability to modulate gene expression through Watson-Crick base pairing with c